Zymeworks Inc. 8-K

What Happened

• On March 2, 2026 Zymeworks BC Inc. (a Zymeworks subsidiary) sold a 30% interest in future royalty payments on Ziihera (zanidatamab‑hrii) to a newly formed special‑purpose Subsidiary for $250.0 million. The Subsidiary immediately borrowed $250.0 million under a term loan from Royalty Pharma Development Funding, LLC (administrative agent and lender). The Loan bears a fixed interest rate, matures on December 31, 2042, and requires total payments of approximately $481.3 million by that Maturity Date (or $412.5 million if repaid in full on or before December 31, 2033), inclusive of interest and fees as described in the filing.
• Zymeworks retains 70% of future Ziihera royalties and will keep all regulatory and commercial milestone payments; full royalty rights revert to Zymeworks once the Loan and obligations under the Loan Agreement are repaid in full. The sale and loan are secured: the Subsidiary granted a security interest in its assets, and Zymeworks BC and its general partner pledged equity interests in the Subsidiary.

Key Details

• Transaction date: March 2, 2026; Purchase price / Loan Amount: $250.0 million.
• Royalty sold: 30% of future Ziihera royalties (subject to certain caps and protections) — Zymeworks keeps 70%.
• Loan maturity: December 31, 2042; total payable by maturity ≈ $481.3M (or $412.5M if repaid by 12/31/2033), inclusive of interest, premiums and fees.
• Material protections: Zymeworks BC is restricted from actions that could reduce or undermine the Royalty Interest; Events of Default include termination of the Jazz or BeOne agreements or a change of control. Lenders’ recourse is limited to the Subsidiary’s collateral and pledged equity interests (no general recourse to Zymeworks’ other assets).

Why It Matters

• Liquidity and capital structure: The transaction provides Zymeworks with $250M in immediate proceeds, which can fund operations, development or bolster the balance sheet without issuing common equity.
• Trade‑off for future cash flow: Investors should note Zymeworks has monetized a portion of future Ziihera royalties (30%) until the loan is repaid, meaning a portion of future product revenue will go to repay the lender and associated fees—though Zymeworks retains the majority (70%) and all milestone payments.
• Risks and protections: The loan is secured by the royalty stream and the Subsidiary’s and related entities’ equity; default triggers (including termination of key license agreements or change of control) could accelerate repayment. However, the lenders have no recourse to Zymeworks’ broader assets beyond the specified collateral and equity pledges.